Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its transaction with Innoviva

Published: May. 24, 2022 at 10:56 AM EDT

MILWAUKEE, May 24, 2022 /PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Innoviva.

AdemiLogo (PRNewsfoto/Ademi LLP)
AdemiLogo (PRNewsfoto/Ademi LLP)(PRNewswire)

Click here to learn how to join the action: or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Entasis' financial outlook and prospects are excellent and yet Entasis holders will receive only $2.20 per share in an all-cash transaction. The transaction agreement unreasonably limits competing bids for Entasis by prohibiting solicitation of further bids, and imposing a significant penalty if Entasis accepts a superior bid. Entasis insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Entasis' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Entasis.

If you own Entasis common stock and wish to obtain additional information, please contact Guri Ademi either at or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:


The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.